Abstract 4025: Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma

Ilié, Marius; Fazzalari, Laetitia; Guibert, Nicolas; Yazbeck, Nathalie; Signetti, Laurie; Hofman, Véronique; Long, Élodie; Zahaf, Katia; Fayada, Julien; Lespinet, Virginie; Bordone, Olivier; Tanga, Virginie; Washetine, Kevin; Vénissac, Nicolas; Mouroux, Jérôme; Marquette, Charles Hugo; Brest, Patrick; Hofman, Paul

doi:10.1158/1538-7445.am2016-4025

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 9 ] CTC concentration in melanoma patients using previous methods is often very low between 0 and 36 per 7.5 mL blood, [ 13 ] and thus insufficient to perform diverse clinical studies such as drug screening or functional in vitro / in vivo studies. [ 15 ] In order to overcome this drawback, simultaneous isolation of more than one circulating marker from same patients will allow for further understanding of melanoma reflecting each circulating marker's characteristic.…”

Section: Introductionmentioning

confidence: 99%

Dual‐Isolation and Profiling of Circulating Tumor Cells and Cancer Exosomes from Blood Samples with Melanoma Using Immunoaffinity‐Based Microfluidic Interfaces

Kang

Hadlock

et al. 2020

Advanced Science

View full text Add to dashboard Cite

Melanoma is among the most aggressive cancers, and its rate of incidence continues to grow. Early detection of melanoma has been hampered due to the lack of promising markers for testing. Recent advances in liquid biopsy have proposed noninvasive alternatives for cancer diagnosis and monitoring. Circulating tumor cells (CTCs) and cancer-exosomes are gaining influence as promising biomarkers because of their cancer-associated molecular markers and signatures. However, technologies that offer the dual-isolation of CTCs and exosomes using a single sample have not been thoroughly developed. The dual-utilization OncoBean (DUO) device is conjugated with melanoma specific antibodies, MCAM and MCSP, enabling simultaneous CTC and exosome isolations. Using blood samples from patients, CTCs and exosomes are specifically isolated from a single sample and then undergo molecular profiling for comprehensive study. Melanoma patients have 0-17CTCs mL −1 and 299 µg exosomal protein mL −1 while healthy donors display fewer than 2CTCs and 75.6 µg of exosomes mL −1 , respectively. It is also demonstrated that both markers express melanoma-associated genes using multiplex qRT-PCR to test for expression pattern of a 96 gene panel. The dual isolation and molecular characterization will allow for further research into melanoma to identify viable markers for disease progression and treatment efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

Dual‐Isolation and Profiling of Circulating Tumor Cells and Cancer Exosomes from Blood Samples with Melanoma Using Immunoaffinity‐Based Microfluidic Interfaces

Kang

Hadlock

et al. 2020

Advanced Science

View full text Add to dashboard Cite

show abstract

“…This is reflected in the diversity of reported approaches toward molecular biomarker analysis. [42] To facilitate the clinical translation of micro/nanomaterial-based systems in biomarker preparation, however, robust and standardized protocols for sample handling are required. With regard to multiomics signature analysis, the following subsections will detail important presample preparation considerations for various molecular biomarker species.…”

Section: Presample Preparation Factors and Considerationsmentioning

confidence: 99%

The Growing Impact of Micro/Nanomaterial‐Based Systems in Precision Oncology: Translating “Multiomics” Technologies

Wuethrich

Dey

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

The field of precision oncology is rapidly progressing toward integrated “multiomics” analysis of multiple molecular species (such as DNA, RNA, or proteins) to provide a more complete profile of tumor heterogeneity. Micro/nanomaterial‐based systems, which leverage the unique properties of miniature materials, are currently well positioned to expand beyond rudimentary biomarker detection toward multiomics signature analysis. To enable clinical translation, the rational design and implementation of miniaturized systems should be driven by the unique clinical challenges present at various crucial cancer stages. This review features micro/nanomaterial‐based systems that are robustly tested on real patient samples for molecular biomarker detection at i) initial cancer screening and/or diagnosis, ii) cancer prognosis and risk stratification, and iii) longitudinal treatment/recurrence monitoring. Furthermore, this review discusses the use of micro/nanomaterials to facilitate sample preparation for different molecular biomarker species. Finally, this review deliberates on the recent paradigm shift of micro/nanomaterial‐based system innovation toward integrated multiomics cancer signature analysis and puts forth insights and perspectives on existing challenges. It is anticipated that this review could stimulate the propagation of new concepts and approaches to kick‐start a new generation of clinically translational technologies that capitalize on multiomics cancer signatures.

show abstract

“…CtDNAs are generally detected using microarray‐based comparative genome hybridization (CGH), single nucleotide polymorphism (SNP) analysis, massively parallel sequencing (MPS), or next‐generation sequencing (NGS). The low sensitivity and the expense of these methods are limitations for the widespread and accurate detection of cfDNAs 313. One strategy to improve the methylation‐specific PCR (MSP) technique, is to use fluorescence‐based (i.e., TaqMan) probes to facilitate the quantitative detection of DNA methylations without requiring further manipulation in the PCR step 314.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications

Azizi

Dianat‐Moghadam

Salehi

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Although considerable efforts have been conducted to diagnose, improve, and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. Perhaps the best hope for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase the current understanding of tumor biology, and will allow nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Owing to their intrinsic physicochemical characteristics, nanostructures (NSs) are valuable tools that have received much attention in nanoimaging. Consequently, rationally designed NSs have been successfully employed in cancer imaging for targeting cancer-specific or cancer-associated molecules and pathways. This review categorizes imaging and targeting approaches according to cancer type, and also highlights some new safe approaches involving membranecoated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells in the hope of developing more precise targeting and multifunctional nanotechnology-based imaging probes in the future.

show abstract

Abstract 4025: Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma

Cited by 8 publications

References 0 publications

Dual‐Isolation and Profiling of Circulating Tumor Cells and Cancer Exosomes from Blood Samples with Melanoma Using Immunoaffinity‐Based Microfluidic Interfaces

Dual‐Isolation and Profiling of Circulating Tumor Cells and Cancer Exosomes from Blood Samples with Melanoma Using Immunoaffinity‐Based Microfluidic Interfaces

The Growing Impact of Micro/Nanomaterial‐Based Systems in Precision Oncology: Translating “Multiomics” Technologies

Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications

Contact Info

Product

Resources

About